Ernexa Therapeutics Stock Price, News & Analysis
Company Description
Ernexa Therapeutics (NASDAQ: ERNAW) is a publicly traded company in the Pharmaceutical Preparations sector.
ERNAW stock has declined 70.0% over the past year. Shares last traded at $0.0300.
On a trailing twelve-month basis, Ernexa Therapeutics reported net income of -$14.1M and diluted earnings per share of $-2.24.
This page provides a comprehensive overview of ERNAW stock, including real-time price data, latest news, SEC filings, insider trading activity, financial highlights, upcoming events, and short interest trends.
Stock Performance
Ernexa Therapeutics (ERNAW) stock last traded at $0.0300. Over the past 12 months, the stock has lost 70.0%.
Latest News
SEC Filings
Ernexa Therapeutics has filed 5 recent SEC filings, including 2 Form 8-K, 1 Form 4, 1 Form S-3/A, 1 Form SCHEDULE 13D/A. The most recent filing was submitted on March 24, 2026. SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all ERNAW SEC filings →
Financial Highlights
operating income reached -$9.3M, and net income was -$14.1M. Diluted earnings per share stood at $-2.24. The company generated -$7.0M in operating cash flow. With a current ratio of 1.01, the company maintains adequate short-term liquidity.
Upcoming Events
Short Interest History
Short interest in Ernexa Therapeutics (ERNAW) currently stands at 1.2 thousand shares, up 503.5% from the previous reporting period, representing 0.0% of the float. Over the past 12 months, short interest has increased by 500.5%. This relatively low short interest suggests limited bearish sentiment.
Days to Cover History
Days to cover for Ernexa Therapeutics (ERNAW) currently stands at 1.0 days. This low days-to-cover ratio indicates high liquidity, allowing short sellers to quickly exit positions if needed.
ERNAW Company Profile & Sector Positioning
Ernexa Therapeutics (ERNAW) operates in the Pharmaceutical Preparations sector and is listed on the NASDAQ.